Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edoxaban - Daiichi Sankyo Company

Drug Profile

Edoxaban - Daiichi Sankyo Company

Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSA

Latest Information Update: 14 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • No development reported Venous thrombosis

Most Recent Events

  • 01 May 2020 Nihon university school of medicine in collaboration with Daiichi Sankyo Company discontinued the phase II PRAEDO AF trial of Edoxaban prior to enrollments initiation in Non-valvular atrial fibrillation patients with stable coronary artery diseases, in Japan (UMIN000032030)
  • 04 Sep 2019 Efficacy and adverse events data from the phase IIIb ENTRUST-AF PCI trial in Embolism (Prevention) and Stroke (Prevention) released by Daiichi Sankyo
  • 31 Aug 2019 Updated efficacy data from the phase III ENGAGE AF-TIMI 48 trial in Atrial fibrillation presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2019)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top